Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SynAct Pharma AB ( (SE:SYNACT) ) has provided an announcement.
SynAct Pharma AB released its interim report for the first quarter of 2025, highlighting significant events and financial developments. The report underscores the company’s ongoing commitment to research and development in inflammatory diseases, which is crucial for its market positioning and stakeholder interests.
More about SynAct Pharma AB
SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation through melanocortin biology.
Average Trading Volume: 187,789
Current Market Cap: SEK888M
See more insights into SYNACT stock on TipRanks’ Stock Analysis page.